Clinical trial CARTITUDE-6
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
| Cancers | |
|---|---|
| Organ | Myeloma |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | EMN |
| EudraCT Identifier | 2023-507632-20-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05257083 |
| Last update |